Highlights

  • Sigma Healthcare (ASX:SIG) reported FY26 revenue of AUD 10.8 billion, up 15.5% on the stated comparable basis.
  • Normalised EBIT reached AUD 1.09 billion, while normalised net profit after tax totalled AUD 732.3 million.
  • The company reported AUD 32.6 million in merger integration synergies for FY26.
  • A new distribution centre in Wiri, Auckland, commenced deliveries during September 2026.

Sigma Healthcare Limited operates a pharmaceutical wholesale and distribution business alongside a franchised community pharmacy network spanning Australia and international markets. The owner of the Chemist Warehouse, Amcal and Discount Drug Stores pharmacy brands recently reported its first full-year results following its combination with Chemist Warehouse Group and commenced deliveries from a new New Zealand distribution centre. On 20 October 2026, Sigma Healthcare (ASX:SIG) was quoted at AUD 2.825, down 0.18% for the trading session, according to the market figures for that date. Its reported operating results and network developments provide the current business context.

Company Business

Sigma Healthcare (ASX:SIG) operates through pharmaceutical wholesale distribution and retail pharmacy franchising. Its wholesale operation supplies prescription medicines, over-the-counter products and front-of-shop merchandise to community pharmacies. Distribution infrastructure and related logistics services connect pharmaceutical suppliers with stores across Australia.

The franchised network uses Chemist Warehouse, Amcal and Discount Drug Stores brands, each serving different customer formats. Franchise operations encompass commercial support, marketing, systems and product ranges; individual pharmacies operate within the applicable ownership and regulatory arrangements. The group also maintains pharmacy-related operations in New Zealand, Ireland, Dubai and China.

Recent Development

In August 2026, Sigma released its results for the financial year ended 30 June. The company described the period as its first full financial year after the merger with Chemist Warehouse Group. Management reported network expansion, progress on integration and higher earnings on its normalised reporting basis.

In September, the company announced that its new Wiri distribution facility in Auckland had started deliveries. The 23,000-square-metre centre handled approximately 50,000 units on its first day and was designed for eventual capacity of up to 500,000 units daily. At launch it supported 78 customers; additional vendor onboarding and automation commissioning remain implementation tasks.

Sigma Healthcare (ASX:SIG) also outlined an electronic data interchange partnership with Pharmx during February 2026, covering wholesale and selected retail ordering infrastructure. The initiative concerns transaction systems and supply-chain coordination rather than a reported change to pharmacy ownership.

Financial Performance and Sector Context

For FY26, group revenue reached AUD 10.8 billion, representing 15.5% growth. Normalised earnings before interest and tax (EBIT) were AUD 1.09 billion, up 20.6%, and the normalised EBIT margin was 10.1%. Normalised net profit after tax increased 22.3% to AUD 732.3 million. The company stated that these growth rates compare with normalised pro-forma FY25 figures.

The Australian segment recorded 14.9% revenue growth and an 18.3% increase in normalised EBIT. International segment EBIT reached AUD 55.8 million, an increase of 91.3%. Sigma reported that its Irish operations achieved profitability for the first time. These measures describe management-defined reporting outcomes and should not be confused with statutory profit figures.

Sigma Healthcare (ASX:SIG) reported net debt of AUD 663 million and a net-debt-to-normalised-EBITDA ratio of 0.57 times. It recognised AUD 32.6 million of integration synergies and outlined a target of AUD 100 million annually by FY29. That target remains dependent on future implementation, rather than representing earnings already realised.

The Australian pharmacy sector is shaped by medicine supply obligations, Pharmaceutical Benefits Scheme settings, dispensing regulation, freight requirements and consumer demand for healthcare and personal-care products. For Sigma, both dispensing-related supply activity and non-prescription retail categories affect operating mix.

Risks to Consider

The group faces operational risks associated with inventory availability, distribution service levels, information systems and the integration of its pharmacy and wholesale activities. Pharmacy regulation and medicine reimbursement arrangements also influence business processes. Network expansion involves staffing, property, technology and execution requirements.

Sigma Healthcare (ASX:SIG) remains exposed to borrowing costs and cash requirements associated with distribution investment and international expansion. Normalised earnings exclude certain adjustments; monitoring statutory outcomes alongside normalised measures is important for understanding reported profitability.

What to Watch Next

The scheduled annual general meeting on 21 October 2026 provides a forthcoming forum for company updates and shareholder questions. Subsequent company disclosures may clarify the pace of pharmacy openings, performance across international markets and the timetable for completing distribution-centre automation.

Other monitoring points include progress toward stated integration synergies, net debt, segment earnings and the contribution from the Wiri facility as more customers and vendors are connected. Any revised financial targets should be assessed when disclosed officially.

Key Insights

Sigma Healthcare (ASX:SIG) has reported growth in FY26 revenue and normalised earnings while extending distribution capacity in New Zealand. Reported net debt and merger synergies provide measurable indicators alongside pharmacy network growth. Future financial releases and operational milestones will show how these business activities develop after the reported period.